Among other mechanisms of tumor-driven immunosuppression, the downregulation of IFNAR1 plays a special role, decreasing the effectiveness of anti-tumor innate and adaptive immune responses, which enables tumor growth and permits the formation of pre-metastatic niches, minimizing the efficiency of anti-cancer type I IFN therapy. The gene discussed is IFNAR1; the disease is cancer.